These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10813040)

  • 1. Phase II begins for T-20.
    AIDS Patient Care STDS; 1999 Sep; 13(9):567-8. PubMed ID: 10813040
    [No Abstract]   [Full Text] [Related]  

  • 2. Enfuvirtide (Fuzeon) for HIV Infection.
    Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. Needle-free T-20.
    TreatmentUpdate; 2005; 17(5):9-10. PubMed ID: 17219660
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).
    TreatmentUpdate; 2005; 17(1):5-6. PubMed ID: 17225316
    [No Abstract]   [Full Text] [Related]  

  • 5. T-20 (Fuzeon) gets priority review.
    AIDS Treat News; 2002 Oct; (384):4-5. PubMed ID: 12434762
    [No Abstract]   [Full Text] [Related]  

  • 6. [HIV infections: further options for combination therapy].
    Hildegard K
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1523. PubMed ID: 12899165
    [No Abstract]   [Full Text] [Related]  

  • 7. [On the path to "e-HAART"? Glimpse at salvage therapy].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():24-5. PubMed ID: 11373771
    [No Abstract]   [Full Text] [Related]  

  • 8. Three new drugs approved by FDA.
    Hoyt G
    Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579
    [No Abstract]   [Full Text] [Related]  

  • 9. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
    Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
    MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.
    Grossman H
    AIDS Treat News; 2002 Sep; (383):2-7. PubMed ID: 12765126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M.
    James JS
    AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880
    [No Abstract]   [Full Text] [Related]  

  • 13. T-20: entirely new antiretroviral.
    James JS
    AIDS Treat News; 1997 Sep; (No 279):5-6. PubMed ID: 11364691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfuvirtide, a new treatment for HIV infection.
    Moledina S; Boucher M
    Issues Emerg Health Technol; 2003 Oct; (50):1-6. PubMed ID: 14594020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-1249 development suspended.
    Huff B
    GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
    [No Abstract]   [Full Text] [Related]  

  • 16. Trimeris, Roche pull no-needle Fuzeon bid.
    AIDS Read; 2007 Dec; 17(12):581. PubMed ID: 18178973
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment news: new options for the future.
    Elliot-Lopez C
    Women Alive; 2000; ():7. PubMed ID: 11367320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-20 and Trimeris.
    James JS
    AIDS Treat News; 1998 Apr; (No 293):1-6. PubMed ID: 11365387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
    Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
    Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.